Rucaparib (AG-014699,PF-01367338)

Catalog No.S1098

Rucaparib (AG-014699,PF-01367338) Chemical Structure

Molecular Weight(MW): 421.36

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • For anchorage dependent clonogenic assays, HER2+ breast cancer BT474 cells were seeded at low density in 6-well plates and allowed to adhere overnight. The next day, olaparib and rucaparib were added at the indicated concentrations. Media and drugs were replenished every three days. After 10-15 days, depending on cell proliferation rate, cells were fixed and stained with crystal violet. Images and graphs indicate the results compared to control condition. Data are mean ± S.D. n.s.: non-significant, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.

    Eur J Cancer 2014 50(15), 2725-34. Rucaparib (AG-014699,PF-01367338) purchased from Selleck.

    Total cell extracts of BT-474 cells treated with increasing concentrations of olaparib or rucaparib were subjected to western blot analysis for PARP-1 and poly ADP-ribose (PAR) expression. β-tubulin was used as loading control. Representative images from two separate experiments are shown.

    Eur J Cancer 2014 50(15), 2725-34. Rucaparib (AG-014699,PF-01367338) purchased from Selleck.

  • purified PARP-1 and His-XPA were incubated alone ( lane 7 ), with activated PARP-1 (addition of activated DNA and NAD+, lane 8 ), or in the presence of the PARP inhibitor AG-014699 (lane 9 ). Following the various treatments, His-XPA was pulled down ( IP ) from each sample using cobalt-conjugated magnetic beads.

    J Biol Chem 2012 287, 39824-33. Rucaparib (AG-014699,PF-01367338) purchased from Selleck.

    Three sensitive and three resistant cell lines were treated for 24 h with 0.02% DMSO (negative control) or 10 uM rucaparib. Serving as positive control were cells fixed 30 min after exposure to 2 Gy IR. Image acquisition was performed with a confocal microscope (Leica TCS SP2) using the 100X objective and a 2X optical zoom and oil immersion. Red: γH2AX foci. Green: RAD51 foci. *P < 0.05 **P < 0.01 ***P < 0.001. Fluorescence microscopy images of DAPI-stained rucaparib-sensitive (HN4) and rucaparib-resistant (SAS) HNC cell lines treated with DMSO, 2 Gy or 10 uM rucaparib for 24 h.

    Oral Oncol 2014 50(9), 825-31. Rucaparib (AG-014699,PF-01367338) purchased from Selleck.

  • Antitumor effects of transfecting of INPP4B gene combined with PARP inhibitor treatment on PC3 cells. (A) The change of cell number and shape under the microscope. (B) The viability of PC3 cells measured using CCK-8. (C) The cell cycle phase distribution of PC3 detected by flow cytometry. (D) Apoptosis of PC3 cells detected using annexin V-FITC/PI staining. (Asterisks denote statistical significance between Lenti-INPP4B+PARP inhibitor and Lenti-INPP4B and PARP inhibitor treatment, *P<0.05).

    Urol Oncol 2014 32(5), 720-6. Rucaparib (AG-014699,PF-01367338) purchased from Selleck.

    in vivo suppression of PAR formation by the PARP inhibitor AG-014699 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AG-014699 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.
     
     

     

    Dr. David Schrmann from University of Base. Rucaparib (AG-014699,PF-01367338) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.
Features The first PARP inhibitor used in clinical trials combined with temozolomide.
Targets
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
In vitro

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. [1] [2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. [3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 MXzGeY5kfGmxbjDBd5NigQ>? MoP5NE4yNzFxNUCwM|ExODBibl2= NXyyW2g{cW6qaXLpeJMhWEGUUDDhZ5Rqfmm2eTDheEB{fGG{dHnu[{Bkd26lZYLueJJifGmxbjDv[kA2ODBibl2= NX7jZmVkOjVzMki0OVU>
BT474 Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD1T3kyPTByIH7N MXyxNQKBmzF3wrDk NWniOYxYemWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? M2GyVVI2OTJ6NEW1
SKBR3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\jVYQ2ODBibl2= MmfINVDjiJNzNdMg[C=> MYXy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKHSqZTDmc5VzKGyrbnXzJIFv\CC|aXfubYZq[2GwdHz5 NVvRSYF6OjVzMki0OVU>
AU565 NH\UV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX6OVAxKG6P NHzzV2IyOOLCk{G1xsBl NUjpSGs2emWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? M4\FOVI2OTJ6NEW1
EFM192A MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofYOVAxKG6P M{iyPFEx6oDVMUZCpIQ> MoOzdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> MWSyOVEzQDR3NR?=
MDA-MB-231 NEnpVphHfW6ldHnvckBCe3OjeR?= MYqxNE8zOC92MDFOwG0> NF76SoozPCCq NXy4NpN[cW6lcnXhd4V{KHBvQVvUJIxmfmWuczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWH2PVRjOjR2MkCxOVI>
MDA-MB-231 M4jRW2NmdGxiVnnhZoltcXS7IFHzd4F6 NYHSTlRkOC5zLUSwJO69VQ>? NGD3XYczPCCq M{LKU2lEPTEkgJm95qCKOTdwN{hCpO69VQ>? M2LlW|I1PDJyMUWy
MDA-MB-231 MVPBdI9xfG:|aYOgRZN{[Xl? M1LyelExNzJyL{SwJO69VQ>? NYjJ[ZlROjRiaB?= MmnJbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NVTuOGc{OjR2MkCxOVI>
MDA-MB-231 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX5NXB4OTBxMkCvOFAh|ryP MkHqNlQhcA>? M{PKS4Jtd2OtczDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKGmwIFeyM20heGijc3W= MoS4NlQ1OjBzNUK=
H460 Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LHNlQxOCCwTR?= NHvDVFEzPMLiaB?= MXvpcoNz\WG|ZYOgZ4VtdHWuYYKgdoFlcW:|ZX7zbZRqfmm2eR?= NVe1RllTOjR2MUG2NVE>
A549  MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rWSFQxOCCwTR?= NXX0RZpzOjUEoHi= NXLTSlBvcW6lcnXhd4V{KGOnbHz1cIFzKHKjZHnvd4Vve2m2aY\peJk> M13ke|I1PDFzNkGx
DT40 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW3TWM2OD1{MTDuUS=> MmfHNlQ{PTZ6MUO=
DU145 M2\NTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r0NGlEPTB;MUigcm0> Ml;DNlQ{PTZ6MUO=
COLO704 M{e1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\oN4Q3UUN3ME2yMlUzKMLzIECuOlch|ryP MkjENlM4Ojl2MEK=
OVMANAb MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXSc3pKSzVyPUKuOVghyrFiMD6zPEDPxE1? NVrId5V[OjN5Mkm0NFI>
OV177 NEPFPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG0b5pKSzVyPUKuO|ghyrFiMD63NUDPxE1? NFOze2szOzd{OUSwNi=>
OAW28 NIXYR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPiTWM2OD1|Lk[xJOKyKDBwMkig{txO NGLz[YYzOzd{OUSwNi=>
OVSAHO NEfOfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\rXWlxUUN3ME2zMlY1KMLzIECuN|Mh|ryP MmOzNlM4Ojl2MEK=
OVKATE NFjtZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrDTWM2OD1|Lk[0JOKyKDFwN{mg{txO MoLvNlM4Ojl2MEK=
OVCAR3 NFy0T5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLTeFBtUUN3ME2zMlc1KMLzIECuOFAh|ryP MUWyN|czQTRyMh?=
PEO14 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzWNo1nUUN3ME2zMlg1KMLzIECuO|Yh|ryP Ml3YNlM4Ojl2MEK=
A2780 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTNwOUSgxtEhOC5{NTFOwG0> MUmyN|czQTRyMh?=
OVTOKO MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXxOIRKSzVyPUSuNVQhyrFiMT61N{DPxE1? NFqxV4kzOzd{OUSwNi=>
KURAMOCHIb MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHNTWM2OD12LkO0JOKyKDBwMkmg{txO Ml\VNlM4Ojl2MEK=
TOV21G NF3TboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\qVYpkUUN3ME21MlA4KMLzIEGuN|Ah|ryP NYTtVYVjOjN5Mkm0NFI>
OVISE MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPlRplQUUN3ME21MlY5KMLzIECuNlMh|ryP MoO3NlM4Ojl2MEK=
KK MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnVTWM2OD14LkG1JOKyKDFwNEKg{txO NXf2R2FPOjN5Mkm0NFI>
RMUGS NHTCcJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDoNllKSzVyPUeuNFMhyrFiMT64N{DPxE1? MlLpNlM4Ojl2MEK=
PEO6 NYHVcXFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3XWHpOUUN3ME23MlA3KMLzIECuO|Qh|ryP NYnKcHBtOjN5Mkm0NFI>
OVCA429 M1;2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnwcXNKSzVyPUiuNlkhyrFiMT62OEDPxE1? MYqyN|czQTRyMh?=
OV167 NHXXUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7hS|JnUUN3ME24MlM{KMLzIEGuNVgh|ryP NWPGU2w2OjN5Mkm0NFI>
RMG1 NHjpclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXBe|lmUUN3ME25MlMzKMLzIEKuN|Yh|ryP MWeyN|czQTRyMh?=
OVCAR5 M2jUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoKxTWM2OD17LkWwJOKyKDJwNUmg{txO MW[yN|czQTRyMh?=
EFO21 MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTlwOUKgxtEhOS56NzFOwG0> NXSybXFnOjN5Mkm0NFI>
ES2 MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFyLkGyJOKyKDFwMkOg{txO NETBdIUzOzd{OUSwNi=>
Tyk-nu MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkmzTWM2OD1zMD6yNEDDuSBzLkGyJO69VQ>? M{HXe|I{PzJ7NECy
CAOV3 MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz5TWM2OD1zMD6zO{DDuSByLki3JO69VQ>? M2XDTVI{PzJ7NECy
OV207 M4\NTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzHSpZKSzVyPUGyMlI4KMLzIECuN|Ih|ryP NFPkUJozOzd{OUSwNi=>
HEY MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF|LkCxJOKyKDBwN{Wg{txO NIfRT28zOzd{OUSwNi=>
DOV13 NHrmVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRjF3IN88US=> MUWyN|czQTRyMh?=
EFO27 NIK5OZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRjF3IN88US=> Mn3kNlM4Ojl2MEK=
HEY C2 M3W0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTCS3ZKSzVyPkG1JO69VQ>? NEjPV|gzOzd{OUSwNi=>
KOC-7cc MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\MU4gxUUN3ME6xOUDPxE1? M{DDR|I{PzJ7NECy
MCASb MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4OxeGlEPTB-MUWg{txO NVrnRXZFOjN5Mkm0NFI>
OAW42 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkCxTWM2OD5zNTFOwG0> MojzNlM4Ojl2MEK=
OV2008 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13yS2lEPTB-MUWg{txO M1i0N|I{PzJ7NECy
OV90 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHvWlh2UUN3ME6xOUDPxE1? M3z5NVI{PzJ7NECy
OVCA420b MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWToT3ZjUUN3ME6xOUDPxE1? NXfQVII6OjN5Mkm0NFI>
OVCA432 NG\zUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRjF3IN88US=> M3H4VVI{PzJ7NECy
PEA2 NF7WSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr3WnRJUUN3ME6xOUDPxE1? NIPzSGozOzd{OUSwNi=>
SKOV3 M1fid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRjF3IN88US=> NGfYbJozOzd{OUSwNi=>
TOV112D NHLvUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnGTYUxNTNizszN MWfJR|UxRjF3IN88US=> M1Gy[|I{PzJ7NECy
C4-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr6dVcxNTNizszN MoXoNVQh\A>? NH;3Xo1FVVOR MXrk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 MlLvNlM2PjV{NES=
PC3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVqwMVMh|ryP MX2xOEBl Mmq5SG1UVw>? MkSy[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? M3PZWFI{PTZ3MkS0
DU145 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHU[FRJOC1|IN88US=> NH3T[nEyPCCm NUDYcWF6TE2VTx?= MoLx[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? MVyyN|U3PTJ2NB?=
VCaP  NVzmV2s4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e5OlAuOyEQvF2= MVmxOEBl NW\6OmhXTE2VTx?= MkPB[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? MmX2NlM2PjV{NES=
LNCaP  Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvhW5JPOC1|IN88US=> M2TWTFE1KGR? MVTEUXNQ NVnvbFJT\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= NYLqTVZZOjN3NkWyOFQ>
MDA-MB-468 NFzxR|VE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MortTWM2OD17Lkeg{txO MoLGNlI3PzhzNkG=
MDA-MB-231 M3zQdWNmdGxiVnnhZoltcXS7IFHzd4F6 NGOxR4hKSzVyPUGzJO69VQ>? M{jqTFIzPjd6MU[x
Cal-51 M3HR[mNmdGxiVnnhZoltcXS7IFHzd4F6 NEHWU5ZKSzVyPUiuOkDPxE1? MlrNNlI3PzhzNkG=

... Click to View More Cell Line Experimental Data

In vivo Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. [4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. [5]

Protocol

Kinase Assay:[1]
+ Expand

Ki Determination:

Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.
Cell Research:[4]
+ Expand
  • Cell lines: D425Med, D283Med and D384Med cells
  • Concentrations: 0.4 μM
  • Incubation Time: 3 or 5 days
  • Method: Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 103, 3 × 103 and 3 × 103, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: CD-1 nude mice bearing established D283Med xenografts
  • Formulation: Normal saline
  • Dosages: 1 mg/kg
  • Administration: One or four daily by i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.35 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.36
Formula

C19H18FN3O.H3PO4

CAS No. 459868-92-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02975934 Recruiting Metastatic Castration Resistant Prostate Cancer Clovis Oncology, Inc.|Foundation Medicine January 2017 Phase 3
NCT02986100 Recruiting Solid Tumor Clovis Oncology, Inc. November 2016 Phase 1
NCT02952534 Recruiting Metastatic Castration Resistant Prostate Cancer Clovis Oncology, Inc.|Foundation Medicine November 2016 Phase 2
NCT02855944 Recruiting Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer Clovis Oncology, Inc.|Foundation Medicine September 2016 Phase 3
NCT02740712 Recruiting Neoplasms Clovis Oncology, Inc. March 2016 Phase 1
NCT02505048 Recruiting Metastatic Breast Cancer UNICANCER|Clovis Oncology, Inc.|Fondation ARC March 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Rucaparib (AG-014699,PF-01367338) | Rucaparib (AG-014699,PF-01367338) supplier | purchase Rucaparib (AG-014699,PF-01367338) | Rucaparib (AG-014699,PF-01367338) cost | Rucaparib (AG-014699,PF-01367338) manufacturer | order Rucaparib (AG-014699,PF-01367338) | Rucaparib (AG-014699,PF-01367338) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID